This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This TAF1A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 68-97 amino acids from the N-terminal region of human TAF1A.
TAF1A
Reaktivität: Human
ELISA
Wirt: Kaninchen
Polyclonal
HRP
Applikationshinweise
For WB starting dilution is: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
TAF1A
(TATA Box Binding Protein (TBP)-Associated Factor, RNA Polymerase I, A, 48kDa (TAF1A))
TAFI48 antikoerper, mTAFI48 antikoerper, MGC:17061 antikoerper, RAFI48 antikoerper, SL1 antikoerper, TATA-box binding protein associated factor, RNA polymerase I, A antikoerper, TATA-box binding protein associated factor, RNA polymerase I subunit A antikoerper, Taf1a antikoerper, TAF1A antikoerper
Hintergrund
Initiation of transcription by RNA polymerase I requires the formation of a complex composed of the TATA-binding protein (TBP) and three TBP-associated factors (TAFs) specific for RNA polymerase I. This complex, known as SL1, binds to the core promoter of ribosomal RNA genes to position the polymerase properly and acts as a channel for regulatory signals. This gene encodes the smallest SL1-specific TAF. Two transcripts encoding different isoforms have been identified.